Avlar BioVentures

Avlar BioVentures

Avlar BioVentures was a Cambridge based venture capital firm focused on investments in biopharmaceutical, small molecule drug discovery, epigenetics, medical technology and biotechnology based companies.

Avlar BioVentures was a Cambridge, England based venture capital firm. They raised €150 million across Avlar BioVentures Fund I, Avlar BioVentures Fund II, and the First Cambridge Gateway Fund. They focus on investments in biopharmaceutical, small molecule drug discovery, epigenetics, medical technology, and biotechnology based companies.

Avlar BioVentures was founded in 1999 by Alan Goodman and Daniel Roach.

Investment

Avlar BioVentures made investments in Intercytex Group, De Novo Pharmaceuticals, Purely Proteins Limited, CellCentric, Takeda Cambridge, Amura, NXVISION, and Crescendo Biologics.

Avlar BioVentures exited their investment in NXVISION.

Timeline

Funded Companies

Company
Industry
Website
Location
NXVISION
5 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.